» Articles » PMID: 24705897

SOCS Proteins in Regulation of Receptor Tyrosine Kinase Signaling

Overview
Publisher Springer
Specialty Biology
Date 2014 Apr 8
PMID 24705897
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Receptor tyrosine kinases (RTKs) are a family of cell surface receptors that play critical roles in signal transduction from extracellular stimuli. Many in this family of kinases are overexpressed or mutated in human malignancies and thus became an attractive drug target for cancer treatment. The signaling mediated by RTKs must be tightly regulated by interacting proteins including protein-tyrosine phosphatases and ubiquitin ligases. The suppressors of cytokine signaling (SOCS) family proteins are well-known negative regulators of cytokine receptors signaling consisting of eight structurally similar proteins, SOCS1-7, and cytokine-inducible SH2-containing protein (CIS). A key feature of this family of proteins is the presence of an SH2 domain and a SOCS box. Recent studies suggest that SOCS proteins also play a role in RTK signaling. Activation of RTK results in transcriptional activation of SOCS-encoding genes. These proteins associate with RTKs through their SH2 domains and subsequently recruit the E3 ubiquitin machinery through the SOCS box, and thereby limit receptor stability by inducing ubiquitination. In a similar fashion, SOCS proteins negatively regulate mitogenic signaling by RTKs. It is also evident that RTKs can sometimes bypass SOCS regulation and SOCS proteins can even potentiate RTKs-mediated mitogenic signaling. Thus, apart from negative regulation of receptor signaling, SOCS proteins may also influence signaling in other ways.

Citing Articles

Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages.

Sato T, Sugiyama D, Koseki J, Kojima Y, Hattori S, Sone K JCI Insight. 2025; 10(1.

PMID: 39782686 PMC: 11721313. DOI: 10.1172/jci.insight.178146.


SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation.

Morelli M, Madonna S, Albanesi C Front Immunol. 2024; 15:1393799.

PMID: 38975347 PMC: 11224294. DOI: 10.3389/fimmu.2024.1393799.


Evidence That Peripheral Leptin Resistance in Omental Adipose Tissue and Liver Correlates with MASLD in Humans.

De la Cruz-Color L, Dominguez-Rosales J, Maldonado-Gonzalez M, Ruiz-Madrigal B, Sanchez Munoz M, Zaragoza-Guerra V Int J Mol Sci. 2024; 25(12).

PMID: 38928125 PMC: 11203746. DOI: 10.3390/ijms25126420.


Inflammatory Skin Diseases: Focus on the Role of Suppressors of Cytokine Signaling (SOCS) Proteins.

Cianciulli A, Calvello R, Porro C, Lofrumento D, Panaro M Cells. 2024; 13(6.

PMID: 38534350 PMC: 10968894. DOI: 10.3390/cells13060505.


JAK/STAT3 signaling in cardiac fibrosis: a promising therapeutic target.

Jiang H, Yang J, Li T, Wang X, Fan Z, Ye Q Front Pharmacol. 2024; 15:1336102.

PMID: 38495094 PMC: 10940489. DOI: 10.3389/fphar.2024.1336102.


References
1.
Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore P, Dikic I . Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol. 2003; 5(5):461-6. DOI: 10.1038/ncb983. View

2.
Qiu X, Zheng J, Guo X, Gao X, Liu H, Tu Y . Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis. Mol Cell Biochem. 2013; 378(1-2):99-106. DOI: 10.1007/s11010-013-1599-5. View

3.
Farabegoli F, Ceccarelli C, Santini D, Taffurelli M . Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma. J Clin Pathol. 2005; 58(10):1046-50. PMC: 1770736. DOI: 10.1136/jcp.2004.024919. View

4.
Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton D . SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem. 2001; 276(51):47944-9. DOI: 10.1074/jbc.M104602200. View

5.
Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T . Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene. 2005; 24(42):6406-17. DOI: 10.1038/sj.onc.1208788. View